Effectiveness and safety of cefazolin vs antistaphylococcal penicillins for methicillin-susceptible Staphylococcus aureus bacteremia: a multicenter real-world evaluation using the international TriNetX database.

Natesan Ramsamy¹, Maïa Simon^2,3, Isabelle Adam², Gema Hernandez⁴, Sarah Williford⁴, Olivier Denquin⁴, Céline Pulcini^3,5, Nathalie Thilly^2,3, Benjamin Lefèvre^1,3

¹CHRU-Nancy, Service des Maladies Infectieuses et Tropicales, Université de Lorraine, Nancy, France.

²Département Méthodologie Promotion Investigation, Université de Lorraine, CHRU-Nancy, Nancy, France.

³Université de Lorraine, INSERM, INSPIIRE, Nancy, France.

⁴TriNetX LLC, Cambridge, Massachusetts, USA.

⁵CHRU-Nancy, Centre Régional en Antibiothérapie du Grand Est AntibioEst, Université de Lorraine, Nancy, France.

PubMed DOI

Abstract

This study aimed to evaluate the effectiveness and safety of cefazolin vs antistaphylococcal penicillins (ASPs) in the treatment of methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia. This phase IV, retrospective, comparative-effectiveness, multicenter study used data extracted from the international TriNetX analytics platform. Eligible patients developed monomicrobial MSSA bacteremia…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.